Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Critical Insights for Oncology Drug Development in Japan and Asia
Novartis runs into production glitch for Kymriah in DLBCL
Wednesday, July 18, 2018
Novartis, whose CAR-T cancer treatment Kymriah was approved less than a year ago, today it has run into some manufacturing issues.
Lilly Oncology’s strategy? Listen to tough talk from patients
Beth Snyder Bulik
Wednesday, July 11, 2018
Lilly Oncology’s marketing chief has some key words for pharma marketers: Don’t lead with data. Put patients’ insights at the forefront instead.
Celgene exec shakeup continues as J&J vet Elkins signs on as CFO
Friday, June 1, 2018
Embattled Celgene already bid goodbye to its COO and business development guru, and now it's moving up its executive ranks to make more changes.
Clovis' Rubraca joins 'three-horse' race
Monday, April 9, 2018
Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.
2017's greatest hits, charted by you
Thursday, December 21, 2017
Megamerger talk, executive moves real and rumored, and layoffs top FiercePharma's list of 10 best-read stories of 2017.
FiercePharmaAsia—Takeda, AstraZeneca, Biocon and more
Friday, December 1, 2017
Takeda offloaded cancer assets, AstraZeneca formed drug discovery JV in China, Biocon's Herceptin biosimilar plant cleared FDA.
FiercePharmaAsia—Teva, Lupin, EOC and more
Friday, November 10, 2017
Teva is reportedly looking to form a Chinese JV, Lupin was hit with an FDA warning letter, EOC Pharma raised $32 million in series B and more.
NICE expands Bayer's Stivarga prospects with move from CDF
Thursday, October 12, 2017
Since NICE took the reins of England’s Cancer Drugs Fund last year, several drugmakers have seen their meds get the boot. Not Bayer.
Most new cancer meds can't improve or extend lives: study
Wednesday, October 4, 2017
Sixty-eight cancer drug indications won EU nods between 2009 and 2013—but most of them did so without showing they could extend or improve life.